Hisamitsu Pharmaceutical Company, Inc.

Ngk Insulators, Inc.

Juridical Foundation the Chemo-sero-therapeutic Research Institute

Chiba-prefecture

Hisamitsu Pharmaceutical Corporation

Takeshi Goto

Katsuhiko Akiyama

Norifumi Tanida

Kazuhisa Yoshitake

Takashi Shimada

Tatsuya Meno

Osamu Iijima

Kazuteru Moriyama

Hiroshi Sorimachi

Hiroaki Maeda

Chikateru Nozaki

Tsutomu Yuasa

Hiroyuki Kubo

Akira Nakagawara

Masaki Hirashima

Yasuko Yoshida

Hideyuki Nishibayashi

Shin Ishii

Saichi Yamada

Takeshi Naruse

Norio Matsukura

Toshio Itoyama

Takahiro Hirata

Fumio Fukai

Jun Aoki

Miki Ohira

Katsuyuki Hamada

Kazuhiro Yuda

Wataru Hattori

Satoshi Suzuki

Naoko Tomizawa

Masaaki Ueki

Shuichi Toriya

A peptide fragment or a series of peptide fragments containing one or more selenocysteine that has a lowered toxicity than selenocystine and that exhibits a cytotoxicity-inhibitory activity. The peptide fragment or a series of peptide fragments according to the present invention has preferably the amino acid sequence from 260th to 362nd amino acid residues from the C-terminal of selenoprotein P, or said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. A screening method for a peptide fragment having the cytotoxicity-inhibitory activity is also provided.

Peptide having cytotoxicity inhibitory activity and method of screening these peptide having cytotoxicity inhibitory activity

A microarray for predicting the prognosis of neuroblastoma, wherein the microarray has 25 to 45 probes related to good prognosis, which are hybridized to a gene transcript whose expression is increased in a good prognosis patient with neuroblastoma and are selected from 96 polynucleotides consisting of the nucleotide sequences of SEQ. ID NOs. 1, 5, 6, 14. 16, 17, 19, 22-24, 28, 29, 31, 37, 39, 40, 43, 44, 47-52, 54, 57-60, 62, 64, 65, 67, 68, 72-75, 77, 78, 80-82, 84, 87, 89-91, 94, 100, 103, 112, 113, 118, 120, 129, 130, 132, 136, 138, 142, 144, 145, 148, 150-153, 155, 158-160, 163-165, 169-171, 173, 174, 177, 178, 180-182, 184, 186, 187, 189, 191, 192, 194, 195, 198-200 or their partial continuous sequences or their complementary strands, and 25 to 45 probes related to poor prognosis, which are hybridized to a gene transcript whose expression is increased in a poor prognosis patient with neuroblastoma and are selected from 104 polynucleotides consisting of the nucleotide sequences of SEQ. ID NOs. 2-4, 7-13, 15, 18, 20, 21, 25-27, 30, 32-36, 38, 41, 42, 45, 46, 53, 55, 56, 61, 63, 66, 69-71, 76, 79, 83, 85, 86, 88, 92, 93, 95-99, 101, 102, 104-111, 114-117, 119, 121-128, 131, 133-135, 137, 139-141, 143, 146, 147, 149, 154, 156, 157, 161, 162, 166-168, 172, 175, 176, 179, 183, 185, 188, 190, 193, 196, 197 or their partial continuous sequences or their complementary strands.

Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma

Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect of lowering blood phosphorus level and another effect of suppressing phosphorus excretion into the urine.

Preventives and/or remedies for hyperphosphatemia

An cross-linked anion exchange resin or a salt thereof obtained by reacting a polymer (A) having amino and/or imino groups in the total number of two or more per molecule with a compound (B) having two or more functional groups capable of reacting with amino and/or imino group contained in the polymer (A). The resin or salt has a water absorption ratio of 4.0 or lower.

Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same

Gene expression base sequences for therapeutic use and drugs for gene therapy

The invention provides solid preparations for oral administration of gene-related drugs comprising a core containing the gene-related drug with a coating which does not disintegrated in small intestines, wherein said preparations can be easily tabletted, remain stable during the preparation process and said drug can be efficiently absorbed in digestive tracts.

Solid preparations for oral administration of drugs relating to genes

An absorption enhancer for the large intestine most suitable for an oral preparation, with a disintegration property in the large intestine, especially the absorption enhancer for the large intestine mixed with a hydrophilic medium and an absorption enhancer is provided.

Enteral sorbefacients

Medicinal compositions for colorectal cancer to be administered to the large intestine by taking advantage of preparations disintegrating in the large intestine, characterized by containing a cyclooxygenase inhibitor and an HMG-CoA reductase inhibitor. These compositions are appropriate for inhibiting the postoperative liver metastasis and recurrence of colorectal cancer.

Medicinal compositions for treating colorectal cancer

Physiologically active peptides

An antisense oligonucleotide characterized in that it hybridizes specifically with chromosomal DNA and/or RNA encoding CXCR4 protein to thereby inhibit the expression of the CXCR4 protein, and a HIV infection inhibitor comprising the antisense oligonucleotide, are disclosed.

HIV infection inhibitors

A sustainedly releasing agent for medicines comprising a non-crosslinked type anion-exchange resin represented by the general formula (I):

Release-sustaining agent for drugs and sustained-release pharmaceutical composition

Disclosed are cholesterol-depressant, coated or non-coated tablets for oral administration, which comprise an anion exchange resin of formula (I):

Anion exchange resin-containing tablets

Tablets containing anion exchange resin

A therapy for a disease, e.g., gastric cancer, comprising endoscopic local administration of a vector having a gene for treatment or cells producing the vector to a lesion to transduce the gene into target cells. The direct in vivo transduction of a gene for treatment into the affected site is expected to produce therapeutic effects specific on the lesion. Since the gene is introduced also into lymph nodes which may have developed a metastatic lesion, both the primary lesion and the metastatic lesion in the surrounding lymph nodes can be treated simultaneously.

Endoscopic administration of an HSV-tk gene to treat digestive organ

Growing community of inventors

Tsukuba, Japan

Takeshi Goto